New Risk • Jun 26
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (58% average daily change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (kr16m revenue, or US$1.6m). Market cap is less than US$100m (€25.9m market cap, or US$29.5m). Tillkännagivande • Jun 19
SoftOx Solutions AS announced that it has received NOK 6.029468 million in funding from Long State Investments Limited On June 18, 2026, the SoftOx Solutions AS closed the transaction. Tillkännagivande • Jun 10
SoftOx Solutions AS announced that it expects to receive NOK 6.029468 million in funding from Long State Investments Limited SoftOx Solutions AS has announced to issue 46 380 523 shares at an issue price of NOK 0.13 per share for gross proceeds of NOK 6,029,467.99 on June 9, 2026. The transaction includes returning investor participation from Long State Investments Limited. Tillkännagivande • Jun 05
SoftOx Solutions AS Enrolls First Participant In SIS-02 Phase 1 Clinical Study SoftOx Solutions AS announced that the first participant has been enrolled in the SIS-02 Phase 1 clinical study in Ireland. The enrollment follows the previously announced approval of the SIS-02 clinical trial application by Ireland’s Health Products Regulatory Authority (HPRA) and marks the formal initiation of the study. The SIS-02 Phase 1 study is designed to evaluate the safety, tolerability, and pulmonary exposure profile of SoftOx Inhalation Solution (“SIS”) following inhaled administration in healthy volunteers and supports the continued development of SIS for defence and biological countermeasure applications. The initiation of SIS-2 represents an important operational milestone for SoftOx and expands the Company’s clinical trial pipeline from one to two ongoing clinical studies. SIS-02 is separate from, and independent of, the Company’s SIS-03 study in chronic lung infections in patients, including cystic fibrosis. Together, the two SIS programs support SoftOx’s strategy to develop SIS as an inhaled anti-infective therapy with potential relevance in both civilian healthcare and defence-related biological preparedness. The SIS-02 program is formally conducted through SoftOx’s wholly owned subsidiary, SoftOx Defense Solutions AS, and is grant-funded through SoftOx’s participation in the COUNTERACT Consortium, which is funded by the European Defence Fund and includes universities, public research institutes, and companies across Europe. The program is also supported by the Norwegian Ministry of Defence. The SIS-02 study is intended to add to the clinical evidence base for SIS and support the planning of subsequent development activities. SoftOx will provide further updates on SIS-02 as the study progresses and when relevant data reviews have been completed. SoftOx Solutions AS is developing SIS, a novel inhaled anti-infective therapy for respiratory infections in the airways and lungs. Delivered by nebulizer, SIS is being developed to address bacterial, viral, and fungal pathogens through local delivery directly at the site of infection, without systemic exposure to the remainder of the human body. Its broad pathogen relevance positions SIS as a distinct therapeutic in respiratory infections. Board Change • May 20
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Tore Duvold was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Sep 27
SoftOx Solutions AS announced that it has received NOK 6 million in funding from Long State Investments Limited On September 26, 2025, SoftOx Solutions AS closed the transaction. Tillkännagivande • Jun 30
SoftOx Solutions AS Appoints Tore Duvold as New Board Member SoftOx Solutions AS at its Annual General Meeting, announced the election of Dr. Tore Duvold as a new member of the Board of Directors. Dr. Duvold brings over 25 years of experience in the life science sector, including leadership roles in biotech, pharma, and public innovation funding. He currently serves as CEO of the Swedish diagnostics company Spermosens AB and has held senior positions at LEO Pharma, Aker Biopharma AS, Innovation Fund Denmark, Edvince AB, and Coegin Pharma. In addition, he has served on the board of Medicon Valley Alliance and been involved in several board roles. Tillkännagivande • Dec 19
SoftOx Solutions AS, Annual General Meeting, Jun 24, 2026 SoftOx Solutions AS, Annual General Meeting, Jun 24, 2026. Tillkännagivande • Sep 13
SoftOx Solutions AS to Appeal Court Ruling in Consultant Bonus Dispute The District Court of Ringerike, Asker, and Bærum has made its ruling in a dispute between SoftOx Solutions AS and a former consultant claiming to have a bonus claim for services rendered in 2022. The district court ruled in favor of the consultant and awarded the consultant approx. NOK 2.5 million plus interest, and NOK 484,000 in compensation including legal costs. The Company believes that the claim has no merits, and the ruling will be appealed. Tillkännagivande • Sep 12
SoftOx Solutions AS Elects Additional Board Members SoftOx Solutions AS at its ExtraOrdinary General Meeting held on 12 September 2024, elected as additional board member: Christian Vinding Thomsen, Vice Chairman of the Board and Eskil Zapffe, board member with an election term until the annual general meeting in 2025. New Risk • Jun 30
New minor risk - Negative shareholders equity The company has negative equity. Total equity: -kr19m This is considered a minor risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. It should be noted that some of the negative equity could be due to large buybacks of stock, which is not as much of a risk as a company with overwhelming debt, but likewise is not sustainable in the long-term. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (37% average weekly change). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 48x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€6.91m market cap, or US$7.41m). Minor Risk Negative equity (-kr19m). Tillkännagivande • May 01
SoftOx Solutions AS has completed a Follow-on Equity Offering in the amount of NOK 2.66919 million. SoftOx Solutions AS has completed a Follow-on Equity Offering in the amount of NOK 2.66919 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 13,345,951
Price\Range: NOK 0.2
Transaction Features: Rights Offering New Risk • Apr 11
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 47x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (47% average weekly change). Earnings have declined by 21% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 47x increase in shares outstanding). Revenue is less than US$1m (kr7.0m revenue, or US$645k). Minor Risks Negative equity (-kr268k). Market cap is less than US$100m (€13.4m market cap, or US$14.4m). New Risk • Apr 05
New minor risk - Negative shareholders equity The company has negative equity. Total equity: -kr268k This is considered a minor risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. It should be noted that some of the negative equity could be due to large buybacks of stock, which is not as much of a risk as a company with overwhelming debt, but likewise is not sustainable in the long-term. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m (kr7.0m revenue, or US$650k). Market cap is less than US$10m (€368.6k market cap, or US$399.5k). Minor Risks Negative equity (-kr268k). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Tillkännagivande • Mar 28
SoftOx Solutions AS has filed a Follow-on Equity Offering in the amount of NOK 25 million. SoftOx Solutions AS has filed a Follow-on Equity Offering in the amount of NOK 25 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 125,000,000
Price\Range: NOK 0.2
Transaction Features: Rights Offering New Risk • Mar 26
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: kr7.0m (US$649k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (32% average weekly change). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m (kr7.0m revenue, or US$649k). Market cap is less than US$10m (€758.7k market cap, or US$821.8k). Minor Risks Negative equity (-kr268k). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Tillkännagivande • Nov 02
SoftOx Solutions AS to Report Q3, 2023 Results on Nov 01, 2023 SoftOx Solutions AS announced that they will report Q3, 2023 results on Nov 01, 2023 New Risk • Sep 27
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 33% per year over the past 5 years. Market cap is less than US$10m (€4.58m market cap, or US$4.81m). Minor Risk Revenue is less than US$5m (kr15m revenue, or US$1.4m). Board Change • Mar 10
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Kari Myren was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Dec 16
Softox Solutions AS Announces Final Report Reaffirms Positive Top Line Phase 1 Results for Softox Biofilm Eradicator SoftOx Solutions AS announces that the Company has received the final report and analysis of its Phase 1 study evaluating the safety and tolerability of SoftOx Biofilm Eradicator (SBE-01) (EudraCT no. 2021-000314-42), SoftOx’s antimicrobial solution for the treatment of chronic wounds. SBE-01 is a first-in-human study investigating the safety, tolerability, and antimicrobial efficacy of single and multiple doses of SBE in patients with chronic leg wounds. The Phase 1 study was divided into two parts: a randomized, blinded, Single Ascending Dose (SAD) phase, followed by an open label, Multiple Ascending Dose (MAD) phase, where patients were treated once-daily or twice-daily over five days. Key findings The final report reaffirms previous findings that SBE is safe and well-tolerated by patients suffering from chronic leg wounds. There were no statistically significant differences in the evaluation of pain during and after the wound cleaning procedure comparing SBE with placebo. The study found that formulations of SBE consistently reduced the bacterial burden in the wound compared with pre-treatment. There was also evidence of wound healing with a reduction in wound area of between 24 to 36% after just 5 days’ treatment. Tillkännagivande • Oct 20
Softox Solutions AS Announces Approval from the Swedish Chemicals Agency on Disinfection Products Softox Solutions AS received the final approval on its application for the SoftOx biocidal product family for hand- and surface disinfection from the Swedish Chemicals Agency (KemI). This approval allows SoftOx to sell its disinfection products in Sweden. SoftOx can use this approval as a basis for new applications — mutual recognition in sequence — in any European market. As the Swedish authorities have diligently evaluated and approved the application, the mutual recognition process, described in the Biocidal Products Regulation (BPR), is considered a less complex and less expensive process. A safe and effective alternative to alcohol-based disinfectants In addition, this approval may provide opportunities in markets outside Europe that normally rely on either EU or US regulatory decisions. Tillkännagivande • Oct 13
SoftOx Solutions AS announced that it expects to receive NOK 40 million in funding from Aubert Invest AS, Pro AS, Almhaug Bolig AS and other investors SoftOx Solutions AS announced a private placement of convertible loan for gross proceeds of NOK 40,000,000 on October 11, 2022. The transaction will include participation from certain existing shareholders including GH Holding AS for NOK 5,000,000, Aubert Invest AS for NOK 2,500,000, Pro AS for NOK 10,000,000, Østlandske Pensjonsforsikring for NOK 5,300,000, Almhaug Bolig AS for NOK 15,000,000 and Geir Almås for NOK 2,200,000. The transaction has been approved by the board of directors of the company. The transaction is epected to close on October 24, 2022. The loan shall carry interest at a rate of 10% per annum. The subscription price per share on conversion of the loan shall be equal NOK 22.50. Tillkännagivande • Sep 07
SoftOx Solutions AS Announces the End of the SBE Phase 1 Clinical Study for Treatment of Chronic Wounds SoftOx Solutions AS announced the end of the Phase 1 clinical study of the SoftOx Biofilm Eradicator (SBE-01) (EudraCT no. 2021-000314-42), SoftOx’s antimicrobial solution for treatment of chronic wounds. SBE-01 is a first-in-human study investigating the safety, tolerability, and antimicrobial efficacy of single and multiple doses of the SoftOx Biofilm Eradicator (SBE) in patients with venous leg ulcers. In Phase 1b the company treated the wounds once and twice daily over 5 days. The original study design included three times daily administration for five days; however, the company expects that data from the two first groups are sufficient to document safety, tolerability, and antimicrobial efficacy in clinically relevant treatment schedules in chronic wounds. SBE is in clinical development as an anti-infective treatment for chronic wounds, designed specifically to penetrate and kill pathogens within biofilms. Due to the broad spectrum and multi-targeted antimicrobial effects, SBE has been shown to kill antibiotic resistant bacteria in biofilms without inducing new antimicrobial resistance in vitro. SoftOx has previously published clinical data supporting the association between reduced bacterial burden and improved wound healing. These associations will be further investigated in the planned SBE Phase 2 (SBE-02) study. As previously reported, SBE-01 recruitment was delayed in the early stages of the trial due to the Danish nursing strike in 2021. To maintain overall clinical development timelines, SoftOx has taken the decision to omit the three times daily treatment, stop further patient recruitment and to end the trial. Tillkännagivande • Sep 02
SoftOx Solutions AS Announces Executive Changes in its Subsidiary, SoftOx Defense Solutions AS SoftOx Solutions AS strengthened its leadership team in SoftOx Defense Solutions AS (SDS), a subsidiary of SoftOx, with the appointment of Jørgen Berggrav as Senior Advisor and Johan Christian Harstad as the Project Director. The appointments will take effect, as of September 1, 2022. In addition, Chief Executive Officer of SoftOx Solutions AS, Geir Almås, will act as interim CEO of SDS, succeeding Rune Jomaas, until a suitable successor has been identified. Jørgen Berggrav graduated from the Royal Norwegian Naval Academy (Sjøkrigsskolen) and has served in the submarine force as a ship's officer, ship's commander and operations and training officer. Berggrav has held many diverse roles in the Armed Forces including as Director General in the Ministry of Defence, representative of Europe to the Supreme Allied Commander Transformation and representative of the Chief of Defence at NATO's operational command, SHAPE, commander of the Landsdelskommando Nord-Norge, and staff training at the Bundeswehr Command and Staff College (die Führungsakademie der Bundeswehr) in Germany, the Armed Forces Academy, and Defence Attaché in Finland. In addition, Berggrav has been Chief Principal for HM the King and was appointed rear admiral in 2003. Following his retirement, Berggrav was the Secretary General of the Norwegian Reserve Officers’ Federation for nearly eight years. Johan Christian Harstad is a former submarine commander, and his last position was as deputy leader in the Norwegian Special Operation Forces with the rank of Commodore. Harstad has international experience with the United States Special Operations Command in experimentation and restructuring of military capabilities. He also studied security policy and foreign relations at the US Naval War College. Harstad has served in the Norwegian Armed Forces’ central staff in Oslo and worked for four years in the Ministry of Defence. Berggrav and Harstad’s focus will be to further develop the SoftOx applications to strengthen the military and civilian preparedness against future epidemics, chemical and biological warfare, complex wound infections and challenging conditions in the respiratory tract. Tillkännagivande • Jun 30
SoftOx Solutions AS Announces Clinical Trial Data Published in Acta Dermato-Venereologica SoftOx Solutions AS announced the publication of data from a randomized control trial (RTC) evaluating the wound-healing effect of SoftOx's stabilized hypochlorous acid solution (HOCl) on acute wounds. The results were published in Acta Dermato-Venereologica, a peer-reviewed journal focused on clinical and experimental research in dermatology and venerology. The randomized trial applied a suction blister wound model and randomized 20 healthy volunteers whereby stabilized hypochlorous acid or control (saline) solutions were assigned. The study's primary objective was to evaluate the wound healing properties of HOCI, and the secondary objective was microbiological control, pain levels and safety with stabilized HOCl compared to the control treatment. Wounds were treated and rinsed on days 0, 2 and 4. Wound healing was assessed blindly, and bacterial growth was evaluated as the number of colony-forming units cultured from surface swabs. Stabilized HOCI was found to accelerate early re-epithelialization (wound healing) significantly on day 4 compared with the control group (p=0.00051) and was not inferior to the control solution on day 10 (p<0.0001). In addition, the median bacterial counts in the wounds were significantly lower after treatment with stabilized HOCI compared with the control group directly after treatment, which also lasted over time. Overall, the study demonstrates the immediate and durable antimicrobial action and beneficial effect of stabilized HOCI on acute wounds and suggests that hypochlorous acid is a promising antimicrobial wound rinsing agent. Tillkännagivande • May 20
SoftOx Solutions AS Announces Positive Phase 1 Results for SoftOx Inhalation Solution SoftOx Solutions AS announced top line results from its Phase 1 study evaluating SoftOx Inhalation Solution (SIS). SIS is a novel aqueous formulation of hypochlorous acid (HOCl), a biological oxidant with broad spectrum antimicrobial (antiviral and antibacterial) properties. In this Phase 1, first-in-human study, nebulised SIS achieved the primary objective of safety and tolerability in healthy subjects. There were no observed local tolerability issues, no adverse effects on pulmonary function, and no serious adverse events. SIS-01 is a first-in-human study investigating the safety and tolerability of single and multiple ascending doses of nebulised SIS to healthy subjects. The randomized, double-blind trial was the first systematic, placebo-controlled study investigating the safety and tolerability of inhaled HOCl in humans. A total of 57 healthy volunteers were randomised to receive SIS formulations of up to 100 µg/ml HOCl, four times daily for five days, or a matching placebo regimen. Data from the study demonstrates that an aqueous formulation of HOCl can be administered to the respiratory tract as an aerosol, as evidenced by dose-response effects on safety parameters, which were predominantly mild, even in the most intensive dosing regimen. With these positive results from the Phase 1 study, SoftOx will continue Phase 2 clinical development of SIS. The company is already in the process of preparing Phase 2 documentation and is engaged in dialogue with the European Medical Association. Tillkännagivande • May 12
SoftOx Solutions AS Announces the Last Patient Completes the Last Single-Dose Cohort of the SBE-01 Clinical Study SoftOx Solutions AS (SoftOx) announced that the last patient has completed the last single-dose cohort of the SBE-01 clinical study. This marks the end of the first part (SAD phase 1a) of SBE-01 (EudraCT no. 2021-000314-42). The Safety Monitoring Committee (SMC) has now recommended the study to continue to enter the last phase (MAD phase 1b) based on encouraging safety and antimicrobial effect measures. In this part of the SBE-01 study company will test the recommended SBE-product once or multiple times daily over 5 days. This will further document the safety, tolerability, and antimicrobial efficacy when SBE is administered on a more intense and clinically relevant treatment schedule. The phase 1b will establish a tolerable dose and treatment schedule for SBE to be able to develop it into an effective infection-treatment solution in problematic, non-healing wounds. SBE-01 is the first-in-human (phase 1) study with the SoftOx’s lead wound care product, SBE (SoftOx Biofilm Eradicator), designed to treat infected chronic wounds. Chronic wounds represent a silent epidemic with an estimated 40 million chronic wounds worldwide and two million related amputations annually. As these wounds last on average 12/13 months and recur in up to 70% of patients, they can lead to loss of function and decreased quality of life as well as are a significant cause of morbidity. SoftOx is currently exploring different indications such as venous leg ulcers and diabetic foot ulcers with the aim to improve the treatment and quality of life for these patients. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Chairman Melvin Teigen was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Jan 25
SoftOx Solutions AS Announces Changes Regarding Application for National Approval of Disinfection Products SoftOx Solutions AS has chosen to temporarily withdraw the application. The biocidal products covered by the transitional arrangement will not be affected, and a new application will be submitted by the deadline of 1 July 2022. The transitional arrangement ensures the company's presence in the market. The reason why the company chooses to withdraw the application is a desire to rework and optimize the new application so that it better suits the changed conditions that now apply. When the application was first prepared, it was based on the Norwegian Environment Agency's recommendations and guidelines, which have subsequently proved to be unclear and not applicable, as well as the later lack of coincidence between the Norwegian Environment Agency and the EU Commission's interpretations in significant areas. A new application will be submitted in accordance with the EU Biocidal Regulations by 1 July 2022. The transitional arrangement is therefore valid if a new application is submitted by this date. Tillkännagivande • Jul 20
SoftOx Solutions AS Provides Project Update on SoftOx Biofilm Eradicator SoftOx Solutions AS provided project update on SoftOx Biofilm Eradicator. The first in human study of SoftOx Biofilm Eradicator started as planned at the end of May, but due to the ongoing nurses' strike in Denmark, the company do not expect to be able to admit patients to the study until the strike is over. The strike is expected to last for approximately 10 weeks. The study is therefore expected to be somewhat delayed; however, the company will strive to make up for lost time. Tillkännagivande • Jun 24
SoftOx Solutions' SWIS-02 Study Results Shows Superior Wound Healing SoftOx Solutions AS (SoftOx) announced that the results of the clinical investigation SoftOx Wound Irrigation Solution for acute wounds (SWIS) have been completed. The study, which has been conducted at Bispebjerg University Hospital in Copenhagen, is a confirmatory clinical investigation to document safety and performance of SoftOx Wound Irrigation Solution (SWIS) compared to Normal Saline (NS) in a human wound model. The study showed both significant improvement in wound healing and reduction in bacterial burden compared to Normal Saline (NS), positioning the product as superior towards today’s market leaders. Finishing the clinical development program strengthens the SoftOx platform for further product development. The results from the study “SWIS-02” confirm the excellent safety profile of the SoftOx technology platform, also strengthening the documentation of SoftOx hand disinfectant technology with regards to skin friendliness being superior to today’s alcohol-based hand disinfectant. The company now prepares to file their wound irrigation SWIS for final approval as a Medical Device in Europe. SoftOx Wound Irrigation Solution (SWIS) will become a Medical Device intended for wound rinsing and moistening to prevent infections in all types of acute wounds, such as abrasions, cuts, burns and surgical wounds. SWIS has the potential to become a favoured alternative to the current wound irrigation solutions on the market which have challenges related to safety (side effects, resistance development) and effect. According to market reports from The Insight Partners, the global market size for wound irrigation solutions was estimated at USD 1.6 billion in 2018, and yearly 190 million wounds is treated in hospitals. Finalization of the SWIS-02 study concludes the clinical evaluation part of the SWIS documentation package. SWIS is expected to be the company’s first CE-marked product for the European market. Regarding the wound healing capabilities, the study meets its primary endpoint of re-epithelialization (non-inferior to NS) by day 10 with high significance (p<0.0001). Furthermore, early re-epithelialization at day 4 was significantly better than normal saline (mean 57% versus 43%, p<0.0001). Also, overall usability aspects of SWIS handling were reported to be satisfactory. Once again SWIS demonstrates and confirms previous findings (from SWIS-01) to be safe and well tolerated as a wound irrigation solution for acute wounds and not associated with any major risks. Performance outcomes demonstrate antimicrobial properties with excellent wound healing (re-epithelialization) observations. Tillkännagivande • Jun 09
Softox Solutions AS Announces that the Danish Medicines Agency Has Given Conditional Approval for the First Study in Humans for Softox Inhalation Solution SoftOx Solutions AS announced that the Danish Medicines Agency has given a conditional approval for the first study in humans for SoftOx Inhalation Solution (SIS) for the treatment of respiratory infections. SoftOx Solutions AS (SoftOx) aims to develop an inhalation solution (SIS) for the treatment of respiratory tract infections. This has the potential to be a breakthrough in the future treatment of respiratory infections, including viruses, bacteria and fungal infections. 
